Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Actinium Pharmaceuticals Inc Market Cap
Based on ratings from 4 stock analysts, the Actinium Pharmaceuticals Inc stock price is expected to increase by 225.84% in 12 months. This is calculated by using the average 12-month stock price forecast for Actinium Pharmaceuticals Inc. The lowest target is $2 and the highest is $9.8. Please note analyst price targets are not guaranteed and could be missed completely.
About 4 Wall Street analysts have assigned ATNM 4 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Actinium Pharmaceuticals Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ATNM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ATNM.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $4 | Maintains | Aug 6, 2024 |
| Jason McCarthy Maxim Group | Buy | $5 | Maintains | Aug 6, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $50 | Reiterates | Jul 26, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $50 | Reiterates | Jun 17, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $50 | Reiterates | May 21, 2024 |
| Sudan Loganathan Stephens & Co. | Overweight | $25 | Initiates | May 14, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $50 | Reiterates | May 2, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $21 | Reiterates | Apr 30, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $50 | Reiterates | Apr 29, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $21 | Reiterates | Apr 1, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $50 | Reiterates | Apr 1, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $50 | Reiterates | Mar 26, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $50 | Maintains | Mar 19, 2024 |
| Jason McCarthy Maxim Group | Buy | $30 | Maintains | Mar 19, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $50 | Maintains | Mar 11, 2024 |
| Yuan Zhi B. Riley Securities | Buy | $16 | Maintains | Dec 11, 2023 |
| Yuan Zhi B. Riley Securities | Buy | $20 | Reiterates | Oct 3, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $50 | Reiterates | Sep 7, 2023 |
| Morten Herholdt HSBC | Buy | $11.6 | Initiates | Sep 6, 2023 |
HC Wainwright & Co. | Buy | Maintains | Aug 15, 2023 |
When did it IPO
2012
Staff Count
49
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Sandesh C. Seth M.B.A., M.S.
Market Cap
$55.8M
In 2023, ATNM generated $81,000 in revenue, which was a decrease of -92.14% from the previous year. This can be seen as a signal that ATNM's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 01 Oct 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Actinium Pharmaceuticals (NYSE: ATNM) for potential securities law violations, including misleading statements affecting investors.
Why It Matters - The investigation into Actinium Pharmaceuticals for potential securities law violations may lead to legal risks, impacting investor confidence and stock performance.
Wed, 02 Oct 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Actinium Pharmaceuticals (NYSE: ATNM) for potential securities law violations, including misleading statements affecting investors.
Why It Matters - Potential legal issues for Actinium Pharmaceuticals may lead to financial penalties or reputational damage, impacting stock performance and investor sentiment.
Thu, 03 Oct 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Actinium Pharmaceuticals (NYSE: ATNM) for potential securities law violations, including false statements and undisclosed information affecting investors.
Why It Matters - The investigation by Schall Law Firm into Actinium Pharmaceuticals could indicate potential legal and financial risks for the company, affecting its stock value and investor confidence.
Tue, 01 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - TerraPower Isotopes has commenced commercial-scale production of actinium-225, enabling weekly supply for pharmaceutical use in global clinical trials.
Why It Matters - TerraPower's commercial-scale production of actinium-225 enhances supply for radiopharmaceuticals, potentially increasing revenue and market value amid growing demand in cancer treatment.
Sat, 28 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Actinium Pharmaceuticals (NYSE: ATNM) for potential securities law violations, including false statements or undisclosed information affecting investors.
Why It Matters - Investigation into Actinium Pharmaceuticals for potential securities law violations could signal risks for investors, affecting stock performance and market confidence.
Sun, 29 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Pomerantz LLP is investigating claims on behalf of Actinium Pharmaceuticals investors (NYSE: ATNM). Interested parties should contact Danielle Peyton for more information.
Why It Matters - The investigation suggests potential legal issues for Actinium Pharmaceuticals, which could impact stock performance and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
